Vertex Pharmaceuticals, Inc. (VRTX)
541.69
-5.86
(-1.07%)
USD |
NASDAQ |
Aug 28, 16:00
541.81
+0.12
(+0.02%)
After-Hours: 20:00
Vertex Pharmaceuticals Free Cash Flow : 3.796B for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.796B |
| March 31, 2026 | 3.710B |
| December 31, 2025 | 3.194B |
| September 30, 2025 | 3.337B |
| June 30, 2025 | 3.500B |
| March 31, 2025 | -1.258B |
| December 31, 2024 | -978.00M |
| September 30, 2024 | -1.352B |
| June 30, 2024 | -1.426B |
| March 31, 2024 | 3.479B |
| December 31, 2023 | 3.279B |
| September 30, 2023 | 4.205B |
| June 30, 2023 | 3.879B |
| March 31, 2023 | 3.890B |
| December 31, 2022 | 3.925B |
| September 30, 2022 | 3.814B |
| June 30, 2022 | 3.787B |
| March 31, 2022 | 2.451B |
| December 31, 2021 | 2.408B |
| September 30, 2021 | 1.919B |
| June 30, 2021 | 1.777B |
| March 31, 2021 | 3.048B |
| December 31, 2020 | 2.994B |
| September 30, 2020 | 2.979B |
| June 30, 2020 | 2.557B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.983B |
| December 31, 2019 | 1.494B |
| September 30, 2019 | 1.363B |
| June 30, 2019 | 1.413B |
| March 31, 2019 | 1.258B |
| December 31, 2018 | 1.175B |
| September 30, 2018 | 1.061B |
| June 30, 2018 | 682.12M |
| March 31, 2018 | 554.37M |
| December 31, 2017 | 585.52M |
| September 30, 2017 | 530.63M |
| June 30, 2017 | 600.73M |
| March 31, 2017 | 461.18M |
| December 31, 2016 | 179.53M |
| September 30, 2016 | 21.96M |
| June 30, 2016 | -86.69M |
| March 31, 2016 | -220.11M |
| December 31, 2015 | -410.73M |
| September 30, 2015 | -519.96M |
| June 30, 2015 | -560.11M |
| March 31, 2015 | -591.10M |
| December 31, 2014 | -564.64M |
| September 30, 2014 | -413.47M |
| June 30, 2014 | -348.76M |
| March 31, 2014 | -211.87M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Gilead Sciences, Inc. | 12.94B |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Sionna Therapeutics, Inc. | -76.21M |
| Regeneron Pharmaceuticals, Inc. | 3.575B |
| Biogen, Inc. | 2.49B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 1.125B |
| Cash from Investing (Quarterly) | -45.80M |
| Cash from Financing (Quarterly) | -426.70M |
| Free Cash Flow Per Share (Quarterly) | 3.970 |
| Free Cash Flow to Equity (Quarterly) | 1.022B |
| Free Cash Flow to Firm (Quarterly) | 1.013B |
| Free Cash Flow Yield | 2.73% |